{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011134","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.607607+00:00","generated_at":"2026-05-17T14:19:06.598742+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amphastar licenses three novel peptides from Anji for up to $453M total","bullets":["Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.","First asset: endogenous peptide suppressing multiple cancer types; second: novel peptide-docetaxel conjugate; third: topical VEGFR eye drop for wet AMD.","Upfront $6M ($0.75M earnest + $5.25M), development milestones up to $42M, sales milestones up to $225M, royalties capped at $60M per product.","Anji receives non-exclusive license outside territory; pays Amphastar low single-digit royalties on certain net sales.","Term: 10 years from first commercial sale per product; Amphastar can extend up to additional 10 years or patent expiry."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011134","json":"https://secwatch.observer/filing/0001558370-25-011134.json","markdown":"https://secwatch.observer/filing/0001558370-25-011134.md","text":"https://secwatch.observer/filing/0001558370-25-011134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000155837025011134/0001558370-25-011134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000155837025011134/amph-20250808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:19:06.598742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}